Cargando…

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

BACKGROUND: In several cardiovascular outcome trials (CVOTs), empagliflozin (SGLT-2 inhibitor), sitagliptin (DPP-4 inhibitor) and liraglutide (GLP-1 receptor agonist) + standard of care (SoC) were compared to SoC in patients with type 2 diabetes and established cardiovascular disease (CVD). This stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramos, Mafalda, Men, Peng, Wang, Xu, Ustyugova, Anastasia, Lamotte, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336098/ https://www.ncbi.nlm.nih.gov/pubmed/34348729 http://dx.doi.org/10.1186/s12962-021-00299-z

Ejemplares similares

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
por: Ramos, Mafalda, et al.
Publicado: (2019)

Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
por: Ramos, Mafalda, et al.
Publicado: (2020)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
por: Reifsnider, Odette S, et al.
Publicado: (2021)

The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
por: Ehlers, Lars Holger, et al.
Publicado: (2021)

The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
por: Ehlers, Lars H., et al.
Publicado: (2022)

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
por: Men, Peng, et al.
Publicado: (2020)

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
por: Reifsnider, Odette S., et al.
Publicado: (2020)

Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
por: Balijepalli, Chakrapani, et al.
Publicado: (2018)

Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
por: Bernfort, Lars, et al.
Publicado: (2020)

Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial
por: Kansal, A., et al.
Publicado: (2019)

Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study
por: Thomsen, Reimar W., et al.
Publicado: (2021)

Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark
por: Thomsen, Reimar W., et al.
Publicado: (2022)

Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
por: Nilsson, Kristoffer, et al.
Publicado: (2022)

Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2016)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
por: Kadowaki, Takashi, et al.
Publicado: (2019)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy
por: McCrimmon, Rory J., et al.
Publicado: (2021)

Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
por: Eliasson, Björn, et al.
Publicado: (2019)

Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States
por: Biskupiak, Joseph E, et al.
Publicado: (2023)

Cost-effectiveness of physical activity in the management of COPD patients in the UK
por: Ramos, Mafalda, et al.
Publicado: (2019)

Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study
por: Nyström, Thomas, et al.
Publicado: (2022)

Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice
por: Fitchett, David H
Publicado: (2018)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
por: Zinman, Bernard, et al.
Publicado: (2017)

Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes
por: Deng, Xinru, et al.
Publicado: (2022)

Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China
por: Salem, Ahmed, et al.
Publicado: (2021)

Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
por: Lim, Jayoung, et al.
Publicado: (2022)

Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
por: Ramos, Mafalda, et al.
Publicado: (2016)

Healthcare resource utilization in patients treated with empagliflozin in East Asia
por: Sheu, Wayne H‐H, et al.
Publicado: (2022)

Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States
por: Reifsnider, Odette S., et al.
Publicado: (2022)

CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
por: Ghetti, Gianni, et al.
Publicado: (2023)

Impact of empagliflozin on diabetic kidney disease
por: Koya, Daisuke
Publicado: (2017)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2018)

Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes”
Publicado: (2022)

Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
por: Sang, Haiqiang, et al.
Publicado: (2022)

Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial
por: Attaran, Fereshte, et al.
Publicado: (2023)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
por: Shubrook, Jay H, et al.
Publicado: (2015)

Myopathy secondary to empagliflozin therapy in type 2 diabetes
por: Gao, Frank, et al.
Publicado: (2020)

Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis
por: Memon, Rahat A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9d9a54ovsavs30i4cpknv5fu4v